WO2005023844A1 - グリセロール誘導体で修飾された化合物 - Google Patents
グリセロール誘導体で修飾された化合物 Download PDFInfo
- Publication number
- WO2005023844A1 WO2005023844A1 PCT/JP2004/013187 JP2004013187W WO2005023844A1 WO 2005023844 A1 WO2005023844 A1 WO 2005023844A1 JP 2004013187 W JP2004013187 W JP 2004013187W WO 2005023844 A1 WO2005023844 A1 WO 2005023844A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- fatty acid
- substance
- acid residue
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 154
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title description 74
- 239000000126 substance Substances 0.000 claims abstract description 147
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 50
- 239000010419 fine particle Substances 0.000 claims abstract description 39
- 150000002314 glycerols Chemical class 0.000 claims abstract description 38
- 125000006850 spacer group Chemical group 0.000 claims abstract description 23
- 239000003607 modifier Substances 0.000 claims abstract description 17
- -1 Carboxy, amino, hydroxyl Chemical group 0.000 claims description 162
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 210000003705 ribosome Anatomy 0.000 claims description 37
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 23
- 239000011859 microparticle Substances 0.000 claims description 23
- 229910052783 alkali metal Chemical group 0.000 claims description 17
- 150000001340 alkali metals Chemical group 0.000 claims description 17
- 239000000839 emulsion Substances 0.000 claims description 12
- 150000002148 esters Chemical group 0.000 claims description 12
- 230000009257 reactivity Effects 0.000 claims description 12
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000005471 saturated fatty acid group Chemical group 0.000 claims 15
- 125000005314 unsaturated fatty acid group Chemical group 0.000 claims 15
- 125000004018 acid anhydride group Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 126
- 239000000725 suspension Substances 0.000 description 87
- 239000000243 solution Substances 0.000 description 76
- 229960004679 doxorubicin Drugs 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 239000002502 liposome Substances 0.000 description 56
- 238000006243 chemical reaction Methods 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000000034 method Methods 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 125000000217 alkyl group Chemical group 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 235000011187 glycerol Nutrition 0.000 description 23
- 125000003545 alkoxy group Chemical group 0.000 description 22
- 239000007864 aqueous solution Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 18
- 150000004671 saturated fatty acids Chemical group 0.000 description 18
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- 150000003904 phospholipids Chemical class 0.000 description 16
- 239000004417 polycarbonate Substances 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 229920000515 polycarbonate Polymers 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 239000007979 citrate buffer Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 125000002252 acyl group Chemical group 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 9
- 229920000573 polyethylene Polymers 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000004359 castor oil Chemical class 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Chemical class CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229930186217 Glycolipid Natural products 0.000 description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 5
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 description 5
- 239000002280 amphoteric surfactant Substances 0.000 description 5
- 239000003945 anionic surfactant Substances 0.000 description 5
- 125000003435 aroyl group Chemical group 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 239000003093 cationic surfactant Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 230000002641 glycemic effect Effects 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 4
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 150000003410 sphingosines Chemical class 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 229940014800 succinic anhydride Drugs 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 150000004820 halides Chemical group 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 101100006370 Arabidopsis thaliana CHX2 gene Proteins 0.000 description 2
- 101100006372 Arabidopsis thaliana CHX4 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002338 electrophoretic light scattering Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- OMKJDABLEGUPIE-QFKKPMMVSA-N (10s,13r,14r,17r)-4,4,10,13,14-pentamethyl-17-[(2r)-6-methylhept-5-en-2-yl]-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)C1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@]21C OMKJDABLEGUPIE-QFKKPMMVSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- KMVYGTIPJNGNRD-GKAPJAKFSA-N (2s)-2-amino-3-benzylbutanedioic acid Chemical compound OC(=O)[C@@H](N)C(C(O)=O)CC1=CC=CC=C1 KMVYGTIPJNGNRD-GKAPJAKFSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- JXNPEDYJTDQORS-AVQMFFATSA-N (9e,12e)-octadeca-9,12-dien-1-ol Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCO JXNPEDYJTDQORS-AVQMFFATSA-N 0.000 description 1
- ZFHGXWPMULPQSE-SZGBIDFHSA-N (Z)-(1S)-cis-tefluthrin Chemical compound FC1=C(F)C(C)=C(F)C(F)=C1COC(=O)[C@@H]1C(C)(C)[C@@H]1\C=C(/Cl)C(F)(F)F ZFHGXWPMULPQSE-SZGBIDFHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical class CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- NJJLDGWFBYVRDJ-UHFFFAOYSA-N 2,3,4-trimethyl-n-propylpentan-3-amine Chemical compound CCCNC(C)(C(C)C)C(C)C NJJLDGWFBYVRDJ-UHFFFAOYSA-N 0.000 description 1
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- DSUKUFGNCZKNGB-UHFFFAOYSA-N 2H-1,3-thiazol-2-ide 1-oxide Chemical compound S1([C-]=NC=C1)=O DSUKUFGNCZKNGB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- YXJUEYDETJCBKA-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OCCNCCO YXJUEYDETJCBKA-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- RVIQSSNDHKQZHH-UHFFFAOYSA-N carbonyl diiodide Chemical compound IC(I)=O RVIQSSNDHKQZHH-UHFFFAOYSA-N 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- VICYBMUVWHJEFT-UHFFFAOYSA-N dodecyltrimethylammonium ion Chemical compound CCCCCCCCCCCC[N+](C)(C)C VICYBMUVWHJEFT-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- OMKJDABLEGUPIE-UHFFFAOYSA-N euphone Natural products CC12CCC(=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C OMKJDABLEGUPIE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- HMRROBKAACRWBP-UHFFFAOYSA-N methyl naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=CC2=C1 HMRROBKAACRWBP-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N n-nonadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- KCPNPXFJBCFNRU-UHFFFAOYSA-N pent-4-ene-1,2-diol Chemical group OCC(O)CC=C KCPNPXFJBCFNRU-UHFFFAOYSA-N 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- RYIOLWQRQXDECZ-UHFFFAOYSA-N phosphinous acid Chemical compound PO RYIOLWQRQXDECZ-UHFFFAOYSA-N 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 229920000835 poly(gamma-benzyl-L-glutamate) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001636 sultamicillin tosylate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Definitions
- the present invention relates to a compound in which an amphipathic substance or a hydrophobic substance is modified with a glycerol derivative or a salt thereof, and a fine particle containing the same, which is useful as, for example, a surface modifier for producing a drug carrier.
- Etc. Background art
- a drug delivery system that delivers a drug administered in vivo to a required tissue to a required amount in a required amount
- a drug delivery system that delivers a drug administered in vivo to a required tissue to a required amount in a required amount
- a method of using such fine particles as a drug carrier is known.
- liposomes are used as drug carriers, such as antitumor agents and anti-inflammatory agents.However, when ribosomes are administered intravenously, they are trapped in, for example, the lungs, liver, spleen, etc., and quickly disappear from the blood. It has been known. Therefore, when the target site is a site other than the lung, liver, and spleen, it is difficult to efficiently deliver the drug to, for example, a tumor or an inflammatory site. Therefore, various attempts have been made to increase the blood retention of liposomes, for example, by chemically modifying liposomes with polyethylene glycol (PEG).
- PEG polyethylene glycol
- liposomes whose surfaces are modified with a surface modifying agent containing a PEG derivative can achieve very high ribosome retention in blood (see, for example, Japanese Patent No. 2667051). No., Japanese Patent Publication No. 7-20857, Patent No. 2948246, etc.). It is also known that ribosomes modified with a surface modifying agent containing a polyglycerin derivative (polyglycerin-modified ribosome) increase the retention of ribosomes in blood (see, for example, JP-A-6-228012).
- PEG-modified ribosomes allow drugs to reach tumors efficiently, but the steric hindrance of PEG present on the surface of liposomes is so large that interaction between the drugs and tumor cells can occur.
- Biochimica et Biophysica Acta 2002, 1558, p. 1
- PEG-modified ribosomes reduces blood retention. [Journal of Controlled Release, 2003, vol. 88, p. 35- 42 and J.
- polyglycerin-modified ribosomes aim at retaining ribosomes in blood instead of PEG-modified ribosomes, but their retention in blood is about twice that of unmodified ribosomes, which is not sufficient.
- An object of the present invention is to provide a compound or a salt thereof, in which an amphipathic substance or a hydrophobic substance is modified with a glycerol derivative, or a salt thereof, which is useful as, for example, a surface modifier for producing a drug carrier. It is to provide fine particles and the like.
- the surface modifier in the present invention is one of the components of a drug carrier (for example, fine particles), and part or all of the structure extends outward from the fine carrier on the surface of the carrier.
- the present invention relates to the following (1) to (28).
- the substance to be modified selected from the group consisting of an amphiphilic substance and a hydrophobic substance is represented by the formula (1)
- R is a modified substance selected from the group consisting of the amphipathic substance and the hydrophobic substance or a modified substance selected from the group consisting of the amphipathic substance and the hydrophobic substance and R ⁇ X represents a residue having a reactive group with a spacer for bonding to or a residue containing a group convertible to a reactive group, n represents an integer of 3 or more, and X represents n
- X is 1 or more and (n-1) or less
- ⁇ ⁇ 2 and ⁇ 3 are each independently a single bond or a substituted or unsubstituted alkylene, carbonyl, substituted or unsubstituted imino, 0, s, sulfonyl
- sulfiel represent one or the same or different plurality of any combination selected from the group, Upsilon iota, when Upsilon 2 and Upsilon 3 there are a plurality of structures which are represented by each may be the same or different
- X is 1 or more and (n-1) or less
- ⁇ is 1 or more and ( ⁇ -1) or less
- ⁇ is 1 or more and ( ⁇ _1) or less
- ⁇ is 1 or more and ( ⁇ -1) or less
- R binds R-X with a modified substance selected from the group consisting of an amphipathic substance and a hydrophobic substance or a modified substance selected from the group consisting of the amphipathic substance and a hydrophobic substance
- a modified substance selected from the group consisting of an amphipathic substance and a hydrophobic substance or a modified substance selected from the group consisting of the amphipathic substance and a hydrophobic substance
- the reactivity with a group selected from the group consisting of carboxy, amino, hydroxyl, mercapto, formyl, sulfate, phosphate, phosphonate and their partial structures in the spacer Group or a group that can be converted to the reactive group The compound or a salt thereof according to any one of the above (1) to (8), which is a contained residue.
- R is a carboxylic acid active ester residue, carbonate, maleimide, mercapto, formyl, tresyl, isocyanate, acid anhydride residue, acid halide residue, vinylsulfonyl, hydrazide, amino, hydroxyl group, halogen,
- Equation (14) (3)
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and at least one of R 1 and R 2 is A saturated fatty acid residue or an unsaturated fatty acid residue, wherein R 3 and R 4 are the same or different and each represent an alkylene having 1 to 10 carbon atoms) or a salt thereof.
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and at least one of R 1 and R 2 one is a saturated fatty acid residue or an unsaturated fatty acid residue, R 3 and a compound or a salt thereof represents an alkylene of connexion carbon number 1-10 different was the same or).
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and at least one of R 1 and R 2 One is a saturated fatty acid residue or an unsaturated fatty acid residue, and R 3 and R 4 are the same or different and represent alkylene having 1 to 10 carbon atoms) or a salt thereof.
- R 1 and R 2 are the same or different Represents a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, at least one of R 1 and R 2 is a saturated fatty acid residue or an unsaturated fatty acid residue, and R 3 and are the same or different Represents a C10 alkylene)) or a salt thereof.
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and a small number of R 1 and R 2 At least one is a saturated fatty acid residue or an unsaturated fatty acid residue, and R 3 and R 3 are the same or different and represent alkylene having 1 to 10 carbon atoms) or a salt thereof.
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and at least one of R 1 and R 2 is A saturated or unsaturated fatty acid residue and R 4 is the same Or a different alkylene group having 1 to 10 carbon atoms) or a salt thereof.
- R 1 and R 2 are the same or different and represent a hydrogen atom, a saturated fatty acid residue or an unsaturated fatty acid residue, and at least one of R 1 and R 2 is A saturated fatty acid residue or an unsaturated fatty acid residue, wherein R 3 and R 3 are the same or different and each represent an alkylene having 1 to 10 carbon atoms) or a salt thereof.
- R 3 and R 3 are the same or different and each represent an alkylene having 1 to 10 carbon atoms
- the modified substance selected from the group consisting of an amphipathic substance and a hydrophobic substance, the modified substance selected from the group consisting of the amphiphilic substance and the hydrophobic substance or the amphiphilic substance and A residue and / or a residue containing a group reactive with the spacer or a group convertible to a reactive group for binding the substance to be modified selected from the group consisting of hydrophobic substances and RX; More than
- the modified substance selected from the group consisting of an amphipathic substance and a hydrophobic substance the modified substance selected from the group consisting of the amphiphilic substance and a hydrophobic substance or the amphiphilic substance and the hydrophobic substance
- a glycerol derivative having the following formula includes, in its structure, a group having a reactivity with a substance to be modified selected from the group consisting of an amphipathic substance and a hydrophobic substance, Residue containing a group convertible to a functional group and at least one
- R represents a residue having a group reactive with a substance to be modified selected from the group consisting of the amphiphilic substance and the hydrophobic substance or a group convertible to a group having reactivity, Represents an integer of 3 or more, and X is n-
- Glycerol derivative (hereinafter, referred to as glycerol derivative (1)) represented by the following formula:
- X is R and n
- the group is not particularly limited as long as it is a group capable of bonding with, but preferably has at least one series branched structure.
- the tandem branch structure means that at least one branch of a branch branched into two or more branches further two or more, and this is repeated. Means the structure to be performed. In particular, a structure in which each of the branched chains branched into two or more branches further into two or more, and this is repeated is preferable. Further, the number of branches is preferably two.
- Number contained in the formula (1) of these branched structure particularly are not limited to, more than one (n-1) or is preferably less, n is 2 1 "when it is the inter alia one or more (2 m -2) or less are more preferred.
- a glycerol derivative having a structure represented by the following formula is also preferable.
- the alkylene for example 1 to 8 carbon atoms, straight-chain, branched or cyclic alkylene, more specifically methylene, ethylene, propane - 1, 3 -Ginole, Butane-1,4-Ginole, Pentane-1,5-Ginole, Hexane-1,6-Dil, Heptane-1,7-Dil, Octane-1,8-Dil, Nonane-1,8 -Diyl, decane-1,9-diyl, cyclopropane-1,2-diyl, cyclobutane-1,2-diyl, cyclopentane-1,2-diyl, cyclohexane-1,2-diyl, cyclopentane -1,2-zinole, cyclooctane-1,2-zil and the like.
- substituent in the substituted alkylene examples include the same or different substituents having 1 to 3 substituents, more specifically, a halogen atom, a lower alkyl, an unsaturated hydrocarbon group, an aryl, a lower alkoxy, a hydroxyl group, a oxo group, and a carboxy group. , Asyl, aroyl, amino, etro, cyano, heterocyclic group and the like.
- examples of the halogen atom include each of nitrogen, chlorine, bromine and iodine.
- the lower alkyl moiety of the lower alkyl and the lower alkoxy includes, for example, a linear or branched alkyl having 1 to 8 carbon atoms, more specifically, methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butynole, and isoptinole. , Sec-butylinole, tert-butylinole, pentyl, neopentyl, hexyl, heptyl, octyl and the like.
- Examples of the unsaturated hydrocarbon group include a linear, branched or cyclic unsaturated hydrocarbon group having 1 to 8 carbon atoms, more specifically, butyl, aryl, 1-propenyl, methacryl, 2- Butano-Nole, 1-Penteno-Nore, 2_Hexenyl, 1,3_Pentagenole, 1,3-Hexagenenole, Cyclopenteninole, Cyclopentageninole, Anoregenyl such as Propanolegyl, Pentinole And alkynyl.
- Examples of aryl include aryl having 6 to 14 carbon atoms, more specifically, phenyl, naphthyl, and anthranil.
- acyl examples include a linear, branched or cyclic acyl having 1 to 8 carbon atoms, more specifically, acetyl, propionyl and the like.
- aroyl examples include benzoyl.
- heterocyclic group examples include a nitrogen atom, an oxygen atom, a sulfur atom And 3- to 8-membered heterocyclic groups containing at least one hetero atom such as furyl, phenyl, pyrrolyl, pyridyl, oxazolyl, thiazolyl, imidazolyl, pyrimidinyl, triazinyl, and the like.
- Examples include indolyl, quinolyl, prill, benzoxazolyl, benzothiazolyl, and benzimidazolyl.
- Examples of the substituent in the substituted imino include lower alkyl, aryl and aralkyl.
- examples of the aralkyl include aralkyl having 7 to 13 carbon atoms, more specifically, benzyl, phenethyl, benzhydryl, naphthylmethyl and the like. Lower alkyl and aryl are as defined above.
- R is a residue containing a group that is reactive with a substance to be modified selected from the group consisting of an amphiphilic substance and a hydrophobic substance or a group that can be converted into a group having reactivity.
- the reactive group which is a partial structure of R, is a carboxy, amino, hydroxyl, mercapto, honolemil, or a sulfuric acid residue (sulfonyl, sulfe) in a modified substance selected from the group consisting of an amphipathic substance and a hydrophobic substance.
- phosphoric acid residues phosphono, phosphonoyl, phosphonate, hydroxyoxyphosphoryl, hydrohydroxyphosphorinole, phosphinyl, hydroxyphosphoryl, phosphoryl, etc.
- phosphonic acid residues dihydroxy Phosphaninole, Hydroxoxide Phosphaninole, Hydroxyphosphael, Hydroxyphosphane Le, Hosufuinato etc., etc. or may be any group as long as it can react with their partial structure.
- the group having a reactivity with the substance to be modified selected from the group consisting of an amphiphilic substance and a hydrophobic substance, preferably, a carboxylic acid active ester residue, carbonate, maleimide, mercapto, formyl, tresyl, isocyanate And an acid anhydride residue, an acid halide residue, vinylsulfonyl, hydrazide, amino, halogen and the like.
- a substance to be modified selected from the group consisting of an amphipathic substance and a hydrophobic substance, preferably a hydroxyl group, carboxy, amino, mercapto, formyl, bul, phosphono, halogen And the like.
- the ester having a sulfonate activity in the ester residue of the sulfonate is preferably an ester having a substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, and more specifically, N-hydroxy.
- Sisuccinimide ester, p-nitrophenyles Tenoré, Chiefinoreesthenore, 2,3,5-Triclofenethenoestrenole, 2,4,6-Trichlorofenisleestenole, 2,4,5-Triclofenenoreestenole, Pentachlorophenyl ester, 2,4-dinitrophenyl ester, N-hydroxyphthalimide ester and the like.
- acid anhydride in the acid anhydride residue examples include a carboxylic acid anhydride.
- acid halide residue examples include carboxyl chloride, carbobromide, carbonyl iodide, and carbofluoride.
- the group other than the reactive group of R or the group convertible to the reactive group is not particularly limited as long as it does not inhibit the reaction 1 ", and may be any group.
- alkyl part of the alkyl and alkoxy of R examples include, for example, linear, branched or cyclic alkyl having 1 to 8 carbon atoms, more specifically, methyl, ethyl, n-propyl, isopropylinole, and n-butyl.
- Isoptinole sec-butynole, tert-butynole, pentynole, neopentynole, hexynole, heptyl, octynole, cyclopropynole, cyclobutynole, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
- Halogen atom an unsaturated hydrocarbon group, an alkylene, Ariru, Ashiru, Aroiru per cent and heterocyclic groups, halo Gen atoms that are described in the respective definitions of the YY 2 Oyohi Y 3, unsaturated hydrocarbon group, an alkylene , Aryl, asil, aroyl and compound It has the same meaning as a ring group.
- Examples of the substituent in the substituted alkyl, substituted unsaturated hydrocarbon group, substituted alkylene, substituted aryl, substituted alkoxy, substituted acyl, substituted aryl, and substituted heterocyclic group may be the same or different, and may have 1 to 3 substituents.
- halogen atom an alkyl, an unsaturated hydrocarbon group, an aryl, an alkoxy, a hydroxyl group, an oxo, a carboxy, an acyl, an aroyl, an amino, a nitro, a cyano, a heterocyclic group, and the like, a halogen atom, an alkyl,
- the unsaturated hydrocarbon group, aryl, alkoxy, acyl, arylo and heterocyclic groups are as defined above.
- substituent in the substituted imino examples include, for example, alkyl, unsaturated hydrocarbon, aryl, alkoxy, acyl, aryl, amino, and heterocyclic groups.
- substituent in the substituted amino examples include the same or the same. Differently, there are 1-2 substituents, more specifically, alkyl, unsaturated hydrocarbon, aryl, alkoxy, acyl, aryloyl, amino, heterocyclic, etc.
- Aryl, alkoxy, .acyl, aroyl and heterocyclic groups are as defined above.
- n is not particularly limited as long as it is an integer of 3 or more, but is preferably 2 m (where m is as defined above), more preferably 4 to 10 24 is a (22 to 216).
- the molecular weight of the glycerol derivative (1) is not particularly limited, but preferably has a molecular weight of about 100 to 1,000,000, more preferably 1,000 to 100,000.
- glycerol derivative (1) examples include glycerol derivatives represented by the following formulas (1A), (1B), (1C), (ID), (IE) ⁇ (1F), (1G), and the like. Is raised.
- Glycerol derivatives (I) the reaction known in the normal first organic synthesis method [book edited by the Chemical Society, “Organic Synthesis]: ⁇ IV", Experimental Chemistry 1 9-2 2, Maruzen, I "2 years, etc.
- the glycerol derivative (1) can be obtained by the following general production method.
- R, X and n are as defined above, Hal represents a halogen atom, R A represents a group convertible to a hydrogen atom, R 5 represents a group convertible to R, 6 is (Wherein R A has the same meaning as described above)
- the Hagen atom is as defined above.
- Examples of a group that can be converted to a hydrogen atom include a substituted or unsubstituted lower alkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted silyl, a substituted or unsubstituted acyl, a substituted or unsubstituted acyl group.
- Unsubstituted arylo and the like can be mentioned, among which benzyl and the like are preferable.
- a group convertible to a hydrogen atom may be filed with one of the two R A is together such connexion is formed, for example substituted or unsubstituted alkylene of glycerol units. Of these propane - 2, 2- Diyl, phenylmethylene and the like are preferred.
- the lower alkyl for example, a linear or branched alkyl having 1 to 8 carbon atoms, more specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isoptyl, sec-butynole, tert- Butinole, pentyl, neopentinole, hexinole, heptinole, octyl and the like.
- alicyclic heterocyclic group examples include a 3- to 8-membered monocyclic alicyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and a 3- to 8-membered ring Is a condensed bicyclic or tricyclic condensed alicyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
- Tetrahydropyridinyl Tetrahydroquinolinyl, Tetrahydroisoquinolinyl, Tetrahydrodrobilanyl, Tetrahydrofuranyl, Dihydrobenzofuranyl, Pyrrolidinyl, Piperidino, Piperidinole, Perhydraazepinyl, Perhydroazoshell, Morpholinol, Morpholinyl, Morpholinyl , Piperazinyl, homopiperidino, homopiperazinyl, dioxolanyl, imimi Zolidinyl, imidazolinyl, pyrazolidinyl, indolinyl, isoindolinyl, 2-pyrrolinyl, 2-pyrrolidonyl, 3-pyrrolidonyl, 2-piperidonyl, 3-piperidonyl, 4-piperidonyl, perhydro-2-azepinonyl, perhydrro — 3-azepinonyl, perhydro— 4-
- sylpyaroyl is as defined above.
- phenols include methylene, ethylene, propane-1,3-dinole, and propylene. Tan-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl and the like.
- substituent of the substituted lower alkyl, the substituted alicyclic heterocyclic group, the substituted silyl, the substituted acyl and the substituted aryl include, for example, the same or different substituents having 1 to 3 substituents, more specifically lower alkyl, lower alkoxy. And lower alkoxy, lower alkoxy, aralkyloxy and the like.
- the substituent of the substituted lower alkyl may be an aryl having 1 or 2 substituents.
- the aryl include phenyl and naphthyl.
- the substituent of the substituted aryl includes 1 to 3 substituents, more specifically, lower alkyl, lower alkoxy, lower alkoxy, lower alkoxy, aralkyloxy and the like.
- the lower alkyl portion of lower alkyl, lower alkoxy and lower alkoxy and lower alkoxy have the same meaning as the above lower alkyl
- the aryl portion of aralkyloxy has the same meaning as the above aryl
- the alkylene portion of aralkyloxy is, for example, , Methylene, ethylene, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl and the like.
- substituent of the substituted alkylene examples include the same or different substituents having 1 to 3 substituents, more specifically, lower alkyl, aryl, lower alkoxy and the like.
- the lower alkyl portion of the lower alkyl and the lower alkoxy has the same meaning as the lower alkyl
- 'aryl' has the same meaning as the aryl.
- the group convertible to R is not particularly limited as long as it is a group convertible to R, and includes the same groups as those described in the definition of the group convertible to a hydrogen atom.
- R A has the same meaning as described above), and is not particularly limited as long as it is a group that can be substituted.
- Specific examples include a hydrogen atom, a halogen atom, a hydroxyl group, alkoxy, and alkanoyloxy.
- the halogen atom has the same meaning as described above, and the alkyl portion of alkoxy and alkanoyloxy has the same meaning as the above-mentioned alkyl.
- Compound (c) is epichlorohydrin, epipromohydrin, epifluorhydrin Using ephalohydrin (compound (a)) such as benzene and R A -OH (where R A has the same meaning as described above) in J. Org. Chem. , 1992, Vol. 57, p. 435, Journal Op. 'Medicinal' Chemistry. Med. Chem.), 1995, Vol. 38, No. 10, p. 1673. Can be.
- Compound (c) is prepared by using 1 to 10 moles of R A -Hal (wherein R A and Hal are as defined above) relative to 1 mole of glycerol (compound (b)).
- compound (c) can be used to convert the hydroxyl group of the primary alcohol of compound (b), for example, to green (TW Greene), Protective Group's' in 'power-on''cis' liR (Protective Groups). In Organic Synthesis, third edition), it can also be obtained by protecting according to the method of introducing a protecting group described in John Wiley & Sons Inc. (1999), etc.
- R A- 0H to be reacted with the compound (a) various alcohols such as methanol, ethanol, propanol, tert-p-tyno-le-nor-cone and benzinole-alcohol can be used.
- R A -Hal to be reacted with the compound (b) includes, as R A , benzyl, methyl, ethyl, propyl, tert-butyl, methoxymethyl, methoxetoxymethyl, tetrahydrobilanyl, tetrahydrofuranyl, trihydrenylmethyl, Removable residues such as benzyloxymethyl, triethylsilyl, etc. can be used.
- Commercially available products can be used as the compounds (a) and (b), and the compound (c) can be synthesized according to the method described above. It can be obtained or obtained as a commercial product.
- Compound (j) can be prepared by a method described in Journal of Medicinal Chemistry (J. Med. Chem.), 1995, Vol. 38, p. 1673, or a compound known in ordinary organic synthesis methods. (Organic Chemistry, edited by The Chemical Society of Japan, “Organic Synthesis”: IV), 4th Edition, Experimental Chemistry, Maruzen, 1992, 19-22, etc. , Further, by combining and / or repeating the following reaction steps, compound (e) in which X has a tandem branched structure, and X has n compound (c) residues bonded thereto can be obtained. .
- R 8 represents a group capable of replacing a hydrogen atom.
- Compound (k) is produced by a reaction known in ordinary organic synthesis methods (edited by The Chemical Society of Japan, "Organic Synthesis I-IV", 4th edition Experimental Chemistry, Maruzen, 1992, 19-22, etc.)
- Compound (1) has a structure of H 2 C-CH 2 _NR 8 -CH 2 _C 0 2 H (R 8 represents a hydrogen atom-substitutable group) Is obtained by dimerizing two amines using a linker (crosslinking agent)
- compound (1) is converted to, for example, green (TW Greene), Amines described in Protective Groups in Organic Synthesis, third edition, John Wiley & Sons Inc., 1999, etc. It can be obtained from the protection reaction.
- Compound (h) is a compound having a residue R containing a reactive group or a group convertible to a reactive group using a conventional organic synthesis reaction at the X-terminal hydroxyl group present in compound (e). Bonding force It can be obtained by directly converting the hydroxyl group into a reactive residue.
- the compound (g) can be obtained by reacting the compound (f) with the compound (c) synthesized in the same manner as described above.
- the method of reacting the compound (f) with the compound (c) to obtain the compound (g) includes a substitution reaction of the compound (c) with the R 6 site of the compound (f), which is known in ordinary organic synthesis methods.
- the reaction of the compound (g) can be exemplified by a combination of the following reactions (edited by The Chemical Society of Japan, "Organic Synthesis:! -IV", 4th Ed. Experimental Chemistry, Maruzen, 1992, 19-22).
- compound (h) is obtained.
- compound ( As f) a commercially available compound having a known structure can be used, or a reaction known in ordinary organic synthesis methods [edited by The Chemical Society of Japan, "Organic Synthesis I :: [V], 4th Edition Experimental Chemistry” Lecture, Maruzen, 1992, 19 ⁇ 22 volumes etc.] can be combined to prepare compound (f).
- the compound (h) is subjected to a reaction for removing a protecting group used in a usual organic synthesis reaction [eg, Darline (TW Greene), Protective Group's 'In' Organic, Synthesis Third Edition (Protective Groups in Organic Synthesis, glycerol by removing RA and replacing it with a hydrogen atom in the third edition), Nyon-Wiley-And, John Wiley & Sons Inc., 1999, etc.
- An inductor (1) is obtained.
- the glycerol derivative (1) may be produced by extending the glycerol unit from the -OH end in the opposite direction to X. It is possible. Each reaction step is carried out in an appropriate solvent, preferably dichloromethane, chloroform, N, N-dimethinolefoxide / remamide, dimethinoresnorreoxide, toluene, tetrahydrofuran, acetonitrile, methanol, ethanol, pyridine, water, And in a solvent arbitrarily selected from among these and mixed solvents, at a temperature of ⁇ 20 to 150 ° C. for 1 hour to several days.
- an appropriate solvent preferably dichloromethane, chloroform, N, N-dimethinolefoxide / remamide, dimethinoresnorreoxide, toluene, tetrahydrofuran, acetonitrile, methanol, ethanol, pyridine, water, And in a solvent arbitrarily selected
- Each compound obtained in each step can be purified to the desired purity, or can be purified to any purity by a general purification method such as recrystallization, solvent extraction, silylation gel chromatography, reverse phase chromatography, and general phase chromatography. Can be used for the next step.
- amphipathic substances examples include phospholipids, glycemic glycolipids, sphingoglycolipids, sphingoids, sterols, cationic lipids, lipids such as anionic lipids, and polyhydric alcohol ester-type nonionic interfaces.
- Surfactants such as surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants.
- phospholipid examples include phosphatidylcholine (for example, soybean phosphatidylcholine, egg yolk phosphatidylcholine, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (D0PC), and the like.
- phosphatidylcholine for example, soybean phosphatidylcholine, egg yolk phosphatidylcholine, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), dioleoylphosphatidylcholine (D0PC), and the like.
- Phosphatidyl ethanolamine for example, disteareyl phosphatidylethanomonoamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), etc.), phosphatidylserine, phosphatidic acid, Dalce mouth phospholipids such as phosphatidinoregglyceronole, phosphatidylinositol, and lysophosphatidinorecolin; suphingomyelin, ceramide phosphota Sphingophospholipids such as nolamine, ceramide phosphodostericerol, and ceramide phosphodaliselic phosphoric acid; glycemic phosphonolipids; sphingophosphonolipids; natural lecithin (eg, egg yolk lecithin, soy lecithin, etc.); And natural or synthetic phospholipids such as phosphatidyl
- glycerol glycolipids include, for example, sulfoxyribosyl glyceride, diglycosyl diglyceride, digarata tosyl diglyceride, galactosyl diglyceride, lid, glyco And sildiglyceride. '
- glycosphingolipids examples include galactosyl celeb mouth side, ratatosyl cereb mouth side, ganglioside and the like.
- sphingoids examples include sphingan, icosasphingan, sphingosine, and derivatives thereof.
- derivatives e.g. Sufuinga down, I Kosasu fins cancer, such as Sufuingoshin - the ⁇ 2 - NHC0 (CH 2) in x CH 3 (wherein, X represents an integer of 0-18, among others 6, 12 or 18 Are preferred).
- Examples of sterols include cholesterol, dihydrocholesterol, lanosterone,] 3-sitosterone, campesterone, stigmaster, brassicasterol, enolego castello, fucosterol and the like. can give.
- Examples of cationic lipids include 1,2-dioleoyl-3-trimethylammonium propane (D0TAP) and N- [l- (2,3-dioleyloxy) propyl]--, ⁇ , ⁇ -trimethyl chloride.
- D0TMA 2,3-Dioleoxy --- [2- (sperminecarboxyamide) ethyl] ⁇ , ⁇ dimethyl-1-propanaminium trifluorotrifluoroacetic acid (D0SPA), N- [2,3- Ditetradecyloxy) propyl] _N, N-dimethyl-N-hydroxyshethylammonium bromide (DMRIE), N- [1- (2,3-dioleyloxy) propyl] -N, N-dimethyl-N- Hid.
- D0SPA ⁇ dimethyl-1-propanaminium trifluorotrifluoroacetic acid
- D0SPA N- [2,3- Ditetradecyloxy) propyl] _N, N-dimethyl-N-hydroxyshethylammonium bromide (DMRIE), N- [1- (2,3-dioleyloxy) propyl] -N, N-dimethyl-N
- anionic lipid examples include phosphatidylserine, phosphatidylglycerol, phosphatidylinositol and the like.
- polyhydric alcohol ester type nonionic surfactant examples include fatty acid monodaliseride, fatty acid diglyceride, fatty acid triglyceride, fatty acid sorbitan ester, fatty acid polyoxysorbitan ester, and sucrose fatty acid ester. More specifically, for example, octyldarcoside, digitonin, decanol-N-methyldalcamide and the like can be mentioned.
- anionic surfactant examples include, for example, acyl sarcosine, sodium alkyl sulfate, anoalkyl benzene sulfonate, sodium fatty acid having 7 to 22 carbon atoms, and the like. More specifically, for example, sodium dodecyl sulfate, sodium lauryl sulfate, And sodium cholate, sodium deoxycholate, sodium taurodeoxycholate and the like.
- Examples of the cationic surfactant include an alkylamine salt, an acylamine salt, a quaternary ammonium salt, and an amine derivative. More specifically, for example, primary amine salts, acylaminoethyl cetylamine salts, N-alkylpolyalkylpolyamine salts, fatty acid polyethylene polyamides, cetyltrimethylammonium bromide, dodecyltrimethylammonium Dempromide, alkylpolyoxyethyleneamine, N-alkylaminopropylamine, fatty acid triethanolamine ester and the like.
- amphoteric surfactant examples include 3-[(3-cholamidopropyl) dimethylammo-o] -1-propanesulfonic acid, N-tetradecyl- ⁇ , ⁇ -dimethyl-3_ammono-1-propane. Pansulfonic acid and the like.
- hydrophobic substance examples include an oily substance and a hydrophobic polymer.
- oily substances examples include liquid paraffin, vegetable oil (soy oil, etc.), fatty acid esters having 12 to 30 carbon atoms, castor oil, castor oil derivatives (polyoxyethylene hydrogenated castor oil, etc.), lanolin, lanolin derivatives, silicon, etc. Can be
- hydrophobic polymer examples include polyaspartic acid, poly (] 3-benzylaspartate), poly ( ⁇ -benzylglutamate), poly (] 3_alkylaspartate), poly (lactide), poly ( ⁇ -force prolatataton) ), Poly ( ⁇ -valerolatataton), poly ( ⁇ -petit mouth ratataton), poly (-benzylaspartate-co-asparaginic acid), poly ( ⁇ - benzylglutamate-co-glutamic acid), poly ( ⁇ - Amino acids) and the like.
- the compound of the present invention comprises the above amphiphilic substance or hydrophobic substance, and (ii) a glycerol derivative (1) modified directly or via a spacer (hereinafter referred to as compound (1) ),
- compound (1) a glycerol derivative (1) modified directly or via a spacer
- specific representative examples include, for example, compounds represented by the above formulas (2) to (10) (hereinafter referred to as compounds (2) to (19), respectively) and the like. can give.
- the saturated fatty acid residue or unsaturated fatty acid residue is, for example, a linear or branched saturated or unsaturated fatty acid having 12 to 30 carbon atoms.
- the acryl group portion is specifically exemplified by dodecanoyl, tridecanoyl, te Tradecanoyl, Pentadecanoyl, Hexadecanol, Heptadecanol, Otatadecanoyl, Nonadecanol, Eicosanole, Henicosanoyl, Docosanoyl, Tricosanole, Tetracosanole, Tetracosanole 9 13-Docosenoyl, 15-Tetracosenoyl, 9,12-Octadecadienol, 11,14-Yecosadienoyl, 9,12,15-Octadecatrienoyl, 11,14,17-Eicosatrinoyl, 4, 8, 12, 16-eicosatetraenoyl, 4, 8, 12, 15, 19-docosapentaenoyl, 2-decaylhexadecanoyl, 2-te
- alkali metal atom examples include sodium and potassium.
- Examples of anoalkylene having 1 to 10 carbon atoms include methylene, ethylene, propane-1,2-diyl, propane-2,2-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane- 1,5-Diynole, Hexane-1,6-Diynole, Heptane-1,7-Diynole, Octane-1,8-Diyl, Nonane-1,8-Diyl, Decane-1,9-Diyl .
- a compound in which a PEG moiety in a triton-based surfactant is modified and replaced with a glycerol derivative (1), or a PEG moiety in a Tween-based surfactant is used. And those substituted by modification with the glycerol derivative (1).
- polyoxyethylene alkyl ether / stearyl alcohol mixture polyoxyethylene olenoquinone ether, polyoxyethylene octynolepheno ether, polyoxyethylene oleinoleamin, polyoxyethylene olein / amine — Ter, polyoxyethylene oleyl ether diethanolamine phosphate, polyoxyethylene oleyl ether sodium phosphate, polyoxyethylene hydrogenated castor oil, polyoxyethylene distyrylphenyl ether, polyoxyethylene stearyl alcohol, Polyoxyethylene stearyl ether phosphoric acid, polyoxyethylene cetyl ether, polyoxyethylene cetyl ether / polyethylene distearate Dalicol mixture, polyoxyethylene cetyl ether Sodium phosphate, Porioki shea ethylene Seto steer linoleate ether Honoré, polyoxyethylene sono Levi monooleate Rau rate, polyoxyethylene sorbit beeswax, polyoxyethylene polycyclic Fueniru
- Compound salts include, for example, hydrochloride, hydrobromide, nitrate, sulfate, phosphate, sodium, potassium, magnesium, calcium, ammonium, tetramethylammonium, morpholine addition Salts, piperidine addition salts and the like.
- Modification of an amphipathic substance or a hydrophobic substance with a glycerol derivative (1) is performed, for example, by modifying a reactive group in the glycerol derivative (1) with an amphiphilic substance or a hydrophobic substance.
- the spacer examples include glycerol derivatives) and amphiphilic substances or hydrophobic substances, as long as they can bind to the binding site in each structure.
- examples thereof include substituted or unsubstituted alkylene (the alkylene and the substituted alkylene).
- the substituents on the alkylene have the same meanings as the substituents on the alkylene-substituted alkylene described in the definition of Y 1 Y 2 and Y 3 , respectively, carbonyl, and substituted or unsubstituted imino.
- the substituent in the substituted imino is as defined above), and a straight-chain linking group consisting of one or a plurality of arbitrary combinations of the same or different selected from the group consisting of 0 and S.
- spacers are used, for example, in amphiphiles or hydrophobic substances.
- Xy Amino, Hydroxyl, Mercapto, Honoryl, Sulfuric acid residue (Sulfoel, Sulfenyl, Sulfiel, etc.), Phosphoric acid residue (Phosphono, Phosphonyl, Phosphonate, Hydroxyloxyphosphoryl / Hydroxy, Phosphoric acid) Linole, phosphinoinole, hydroxyphosphoryl, phosphoryl, etc.), phosphonic acid residue (dihydroxyphosphanyl, hydroxypoxidephosphaninole, hydroxyphosphininole, hydroxyphosphandinole, phosphinato, etc.) and the like Bonds to the partial structure via ether bond, amide bond, thioether bond, ester bond, etc.
- the glycerol derivative (1) as a modifier is bound to the spacer in advance and the glycerol derivative (1 ) Can be bound to an amphipathic substance or a hydrophobic substance in the same manner as described above.
- each compound is purified to its original purity or purified to any purity by a general purification method such as recrystallization, solvent extraction, gel chromatography, reverse phase chromatography, or normal phase chromatography. It can be used for the next step.
- a general purification method such as recrystallization, solvent extraction, gel chromatography, reverse phase chromatography, or normal phase chromatography. It can be used for the next step.
- glycerol derivatives (1) are used as chemical modifiers for modifying amphiphilic substances or hydrophobic substances, but some or all of the terminal hydroxyl groups of the glycerol derivative (1) are protected.
- -0R a (wherein, R a has the same meaning as defined above) was as chemical modifier precursors glycerol derivative conductor is, or may be used in the reaction with the amphiphilic or hydrophobic materials.
- the target compound (1) can be obtained in the same manner as in the above-described reaction for removing the protecting group of the compound (h).
- the substance to be modified selected from the group consisting of an amphiphilic substance and a hydrophobic substance is modified with one or a plurality of the same or different combinations of glycerol derivatives (1). It is preferably modified with a glycerol derivative (1) composed of one or the same plural combinations.
- the compound of the present invention can be used as a surface modifier for producing a drug carrier (for example, microparticles capable of holding or containing a drug or the like).
- a drug carrier for example, microparticles capable of holding or containing a drug or the like.
- the compound can also be used as a component of the drug carrier, and has an effect of improving the productivity of the drug carrier.
- the fine particles of the present invention include a compound in which the amphiphilic substance or the hydrophobic substance described in (ii) is modified with a glycerol derivative (I) directly or through a spacer (hereinafter, compound (Referred to as (I)) or a salt thereof, and the compound (I) to be contained may be a plurality of different combinations.
- the compound (I) is obtained by a method similar to the method for preparing compound (1) described above.
- the fine particles may further contain lipids and / or a surfactant, and may have any form.
- lipids and / or a surfactant Preferably those having an average particle size of ⁇ 1000 / im,
- ribosome MUV (Multilamellar Vesicles) multiple layers ribosomes etc., LUV (Lar g e Unilamellar Vesicles ) s SUV (Small Unilamellar Vesicles) one such film ribosomes Etc.), fat emulsions (microcapsules, microspheres, etc.), emulsions (lipid emulsions, microemulsions, etc.), micelles (polymer micelles, lipid micelles, etc.), fine particle crystals (plates, columns, needles, fibers) , Sphere, dice, prism, etc.), and preferably ribosome.
- MUV Multilamellar Vesicles
- LUV Long g e Unilam
- lipids contained in the microparticles include phospholipids, glycolipid glycerides, glycosphingolipids, sphingoids, sterols, cationic lipids, ionic lipids, and polyethylene daricol, which are ether-bonded. (Polyethylene glycolated). Among them, those having a phase transition temperature higher than the in-vivo temperature (35 37 ° C) are preferred, and phospholipids and / or polyethylene glycolated phospholipids are more preferred. .
- surfactant contained in the fine particles examples include a polyhydric alcohol ester type nonionic surfactant, an anionic surfactant, a cationic surfactant, an amphoteric surfactant, and polyethylene glycol. Examples thereof include those bonded with an ether (polyethylene glycol).
- Phospholipids examples thereof include those exemplified in the above (ii), and these may be used alone or in combination.
- lipids composed of at least two or more components selected from the group consisting of hydrogenated soybean phosphatidinorecoline, polyethylene glycolated phospholipids and cholesterol, DSPC, Polyethylene Dalicoldani Phospholipid and cholesterol selected from the group consisting of at least two lipids, yolk phosphatidylcholine D0TAP lipids, yolk phosphatidylcholine, D0TAP and polyethylene glycolated phospholipid Lipids such as lipids, yolk phosphatidylcholine, D0TAP, cholesterol, and polyethylene dalicholated phospholipids are used.
- polyoxysorbitan fatty acid ester, sorbitan fatty acid ester, fatty acid sodium, polyethylene hardened castor oil and the like are preferably used alone or in combination.
- the fine particles of the present invention may contain additives such as a tonicity agent, a film stabilizer, an antioxidant, and a charged substance, if necessary.
- a tonicity agent include glycerin, glucose, sodium chloride and the like.
- the membrane stabilizer include sterols such as cholesterol and the like.
- the antioxidant include tocopherol, citrate, and the like.
- charged substances include stearylamine, dicetylphosphate, ganglioside, and D0TMA (Procedure of the National 'Academy'. Proc. Natl. Acad. Sci. US A, 1987, 84, p. 7413-7417], Dioctadecylamidok, 'Risylspermine (DOGS)
- the fine particles of the present invention can be prepared by a generally known method.
- the above-mentioned lipids and / or surfactant and the compound of the present invention can be further added as necessary.
- the above additive is dissolved in a solvent such as ethanol or ether, and the solvent is distilled off, if necessary, and then a solution to be suspended is added to disperse, emulsify or suspend.
- a solution to be suspended is added to disperse, emulsify or suspend.
- modified fine particles are prepared by a generally known method, and a powder (aqueous solution, aqueous solution or ethanol solution) of the compound of the present invention is added to a preparation liquid (dispersion, emulsification or suspension) of the modified fine particles.
- the fine particles of the present invention can also be prepared by leaving them to stand for a certain period of time, preferably by heating them to a temperature higher than the phase transition temperature of the film, and then allowing them to cool.
- the solution to be suspended examples include distilled water, acidic aqueous solution (aqueous solution such as hydrochloric acid, sulfuric acid, and acetic acid), alkaline aqueous solution (aqueous solution such as sodium hydroxide, calcium hydroxide, and sodium hydrogen carbonate), and buffer solution (phosphate buffer). Liquid), physiological saline, amino acid infusion and the like.
- aqueous solution such as hydrochloric acid, sulfuric acid, and acetic acid
- alkaline aqueous solution aqueous solution such as sodium hydroxide, calcium hydroxide, and sodium hydrogen carbonate
- buffer solution phosphate buffer
- At least one of the microparticles extends outward from the surface of the microparticles (hereinafter referred to as glycerol derivative-modified microparticles, and when the microparticles are, for example, liposomes, similarly referred to as glycerol derivative-modified liposomes).
- the glycerol derivative-modified fine particles can be prepared by using the compound of the present invention as a surface modifier in the preparation of the fine particles of the present invention.
- the use of the compound of the present invention as a surface modifier means that when preparing the fine particles of the present invention, the compound of the present invention is contained so that the compound of the present invention is contained in the outermost layer portion of the fine particles of the present invention. It is to use.
- the fine particles of the present invention can be prepared according to a known preparation method.
- the preparation method include a liposome preparation method of Bangham et al. [Journal, Op. Molecular Biology (J. Mol.
- ribosomes surface modification of ribosomes with polyhydric alcohol ester type nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, polysaccharides or derivatives thereof, polyoxyethylene derivatives, etc. is optionally performed.
- surface-modified ribosomes are also included in the microparticles of the invention [DD Lasic and F. Martin, Stealth Liposomes, America, Cianoresi Press Ink (CRC Press Inc.), 1995,. 93-102].
- the average particle size of the liposome is preferably from 30 to 3000 nm, more preferably from 50 to 500 ⁇ , and most preferably from 60 to 200 nm.
- Methods for adjusting the average particle size of the ribosome include a method of mechanically grinding large multi-layer ribosomes (MLV) using an extrusion method such as mantongoulin, microfluidizer, etc. [Muller, Benita, Baume (RH Muller, S. Benita, B.
- the content of compound (I) or a salt thereof in the microparticles is preferably about 0.01 to 50 mol%. Within 0.1 to 20 mol ° /. Is more preferable.
- microparticles obtained above are modified with substances such as proteins such as antibodies, saccharides, glycolipids, amino acids, nucleic acids, various low molecular weight compounds, and high molecular weight compounds.
- the fine particles obtained by these methods are also included in the fine particles of the present invention.
- it is also possible to further modify the lipid membrane surface with antibodies, proteins, peptides, fatty acids, etc. on the particles obtained above (Radic, Martin et al. D. Lasic and F. Martin), Stenoth Ribosomes (Steelth Liposomes), USA One Press Ink (CRC Press Inc.), 1995, p. 93-102], and those having a lipid membrane surface modified are also included in the fine particles of the present invention.
- the fine particles of the present invention can, for example, hold or enclose a drug or the like. It can be used as a preparation for the purpose of increasing drug accumulation in organs, improving oral and transmucosal drug absorption, and the like.
- any drug that is retained or encapsulated may be, and is not particularly limited, but has, for example, an antitumor agent, a contrast agent, an antibiotic, an antifungal, and Substances, biological components and the like.
- Antitumor agents include, for example, actinomycin D, mitomycin C, chromomycin, doxorubicin, epirubicin, vinorelbine, daunorubicin, aclarubicin, bleomycin, dupromycin, vincristine, vinplastin, vindesine, etoposide, 5-F , Tegafur, cytarabine, enocitabine, ancitabine, taxol, taxotere, cisplatin, cytosine arabinoside, irinotecan, camptothecin, and derivatives thereof.
- contrast agent examples include iohexal, iodixanol, indocyanine lean, sodium iotalamate and the like.
- Antibiotics include, for example, minocycline, tetracycline, piperacillinna trdium, sultamicillin tosylate, amoxicillin, ampicillin, bacampicillin, asposicillin, cefdinir, floxef sodium, cefotiam, cefcapenbiboxyl, cefapole, cefopole Cefazolin sodium, cefazolan, clarithromycin, clindamycin, erythromycin, levofloxacin, tosfloxacin tosylate, ofloxacin, ciprofloxacin, anorebekacin, isepamicin, dibekacin, amikacin, gentamicin, vancomycin, fosfomycin, etc. can give.
- antifungal agents examples include fluconazole, itraconazole, terbinafine, amphotericin B, miconazole, derivatives thereof, and the like.
- Substances having pharmacological activity include, for example, hormones, enzymes, proteins, peptides, amino acids, nucleic acids, genes, antisense RNAs, antisense DNAs, interfering RNA), vitamins, sugars, lipids, synthetic drugs and the like.
- Examples of the biological component include a blood component.
- the suspension of the microparticles prepared by the above method is generally used as it is in the form of an injection.
- oral preparations nasal drops, eye drops, It can also be processed and used as skin, suppositories, inhalants and the like.
- These include pharmaceutically acceptable diluents, excipients, disintegrants, lubricants, binders, surfactants, water, saline, vegetable oil solubilizers, isotonic agents, preservatives, It can be prepared by an ordinary method using an antioxidant or the like.
- an excipient such as lactose is added to the suspension of the microparticles of the present invention and freeze-dried, or a cryopreservative such as glycerin is added and cryopreserved, and these are added together with an appropriate excipient. It may be granulated, dried, etc. according to a conventional method, and processed into oral preparations such as capsules, tablets, granules and the like.
- the average particle size of the ribosomes prepared in Examples 5 to 8 and Comparative Examples 1 to 3 was measured by using an electrophoretic light scattering photometer (ELS) [A model ELS-800, Otsuka Electronics Ltd. (ELS-800, manufactured by Otsuka Electronics Co., Ltd.). )].
- ELS electrophoretic light scattering photometer
- Table 1 shows the results. The average particle size of the two lots is shown in the order of the first lot and the second lot. '
- the average particle size of the glycerol derivative-modified liposomes containing the compound (2) or (4) prepared in Examples 5 to 8 is around 120 nm, and these liposomes are useful as liposomes. It was found to have a size.
- the liposome suspensions prepared in Examples 5 to 8 and Comparative Examples 1 to 3 were subjected to ultracentrifugation (1 hour, 110,000 Xg, 25 ° C). .
- the liposome suspension A and the supernatant obtained by ultracentrifugation were dissolved in a mixed solvent of 2-propanol and water (8/2 (volume / volume)).
- the doxorubicin in the liposome suspension A and the supernatant A was quantified by measuring the absorbance at 497 ⁇ of each solution using a spectrophotometer (U-3210, manufactured by Hitachi, Ltd.).
- ribosome suspension B a ribosome suspension having the same phospholipid concentration as ribosome suspension A and containing no doxorubicin (hereinafter referred to as ribosome suspension B) was prepared, and phospatidylcholine ( PC ) in liposomes was prepared. )) was measured in the same manner as described above.
- the encapsulation rate of doxorubicin in the liposome in each liposome suspension A was calculated by the following equation (1).
- Comparative Example 3 56 From Table 2, it can be seen that the encapsulation rate of doxorubicin in the PEG-modified ribosome prepared in Comparative Example 3 is low, and when the content of PEG-DSPE is increased, the stability of liposomes is significantly reduced, and doxorubicin leaks out. It has been found. On the other hand, the encapsulation rate of doxorubicin in the glycerol derivative-modified ribosomes prepared in Examples 5 to 8 was good, and it was found that these ribosomes were ribosomes having good stability. In other words, it is considered that the ribosome containing the compound of the present invention can maintain stability regardless of the content of compound (1).
- the liposome suspension (administration drug solution) prepared in Examples 7 and 8 and Comparative Examples 1 to 3 was administered under inhaled anesthesia with Jethyl ether. ”'00 (30) 105 rats (body weight: 200 to 300 g, 3 mice per group, 2 Some lots were administered via the left tail vein to the first lot (2 animals and the second lot to J animals) (dose; doxorubicin 0.35 mg / kg). Blood is collected over time from the right tail vein using a heparin-treated capillary, and plasma is obtained by centrifugation (5 min, 8,000 X g, 4 ° C) .Doxorubicin in plasma is obtained by the following method. Quantified. It was diluted 10-fold with the resulting plasma 0.
- doxorubicin a standard solution of doxorubicin was separately prepared, and the calibration curve was obtained by measuring the fluorescence intensity.
- concentrations of doxorubicin in the plasma and in the drug solution were determined based on the calibration curves, and the plasma volume of rats weighing 250 g was determined to be 7.8 mL [Pharmceutical Res., 1993, vol. 10, p. 1093-1095], the amount of doxorubicin remaining in the plasma among the administered amount of doxonorubicin (.
- the amount of doxorubicin in the plasma (%) _ time curve was used to determine the amount of doxorubicin in the plasma from 0 to 24 hours. weight doxorubicin (%) -.
- AUC of (AUC._ 24 hr or) was determined by the trapezoidal method AUC._ 24 hr or values when administered unmodified liposomes prepared in Comparative example 1 as 1, other modifications
- the AUC when ribosomes were administered was compared for 24 hours, and the results are shown in Table 3.
- a ribosome containing the compound of the present invention as a drug carrier, a stronger drug effect can be obtained without increasing the dose of the drug.
- a liposome containing the compound of the present invention can be used.
- Use of the drug as an anti-tumor drug carrier increases the amount of drug transferred to the tumor In addition, effective treatment and reduction of side effects will be possible.
- AUC of doxorubicin when each of PEG-modified ribosomes having different contents of PEG-DSPE prepared in Comparative Examples 2 and 3 was administered.
- the AUC of doxorubicin was obtained even when the content of PEG-DSPE was changed. -Little change in hr values was observed.
- Comparison of the 24hr values shows that the content of the glycerol derivative of compound (4) was changed and the AUC of doxorubicin.
- glycerol derivative-modified ribosomes can further improve and improve the performance required as a drug carrier, such as changes in plasma concentration.
- reaction scheme is shown below.
- Bn represents a benzyl group
- NHS represents N-hydroxysuccinimide
- DSPE distearoylphosphatidylethanolamine.
- Trifluoroacetic acid (5 mL) was added to a dichloromethane solution (45 mL) of compound 3 (2. Og, 1.43 mmol) at room temperature, and the mixture was stirred at the same temperature for 20 hours. After adding a saturated aqueous solution of sodium hydrogencarbonate to the reaction mixture, the mixture was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the solvent was distilled off under reduced pressure to obtain a pale yellow oily compound 4 (1.19 g, yield 64%). ., X H-NMR (CDC1 3, 300MHz) ⁇ (ppm):. 1. 75 (1H, s), 2. 87 (4H, s), 3. 47-3 81 (28H, m), 4. 16 (2H, m), 4.48 (16H, s), 7.00 (2H, d), 7.19-7.31 (40H, m).
- DSPE Distearoyl phosphatidyl ethanolamine
- DSPE 39 rag, 0.052 ramol
- a mixed solvent of dichloromethane (lOraL) and methanol (5 mL) a mixed solvent of dichloromethane (lOraL) and methanol (5 mL)
- Compound 12 150 mg, 0.052 ⁇ ⁇ ol
- the reaction mixture was stirred at room temperature for 18 hours under light protection and an argon atmosphere.
- further DSPE a (20 mg) was ⁇ Ka ⁇ and stirred for 23 hours at 3 3 ° C.
- Lithium oxide is slowly added to the aqueous solution of compound 23 at room temperature, followed by stirring.
- the reaction solution is extracted with dichloromethane.
- the organic layer is washed with a saturated saline solution, dried using anhydrous magnesium sulfate, and filtered.
- the solvent is distilled off under reduced pressure, and the residue is purified by silica gel column chromatography to obtain compound 24.
- Compound 27 is obtained by treating compound 26 under acidic conditions, preferably weakly acidic conditions.
- Compound 27 is obtained by treating compound 38 with Pd (0H) 2 / C in a hydrogen atmosphere at room temperature in a methanol solution in the same manner as compound 7 in Example 1.
- distilled water was added to adjust the doxorubicin concentration to lmg / mL.
- the obtained suspension was heated at 70 ° C. for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin.
- To the suspension of the unmodified liposome containing the doxorubicin was added the ethanol solution of the compound (2) obtained in Example 1 (ethanol amount: 1% by volume of the suspension of the unmodified ribosome containing the doxorubicin).
- the compound (2) was added such that the content of the compound (2) was 6.7 mol% of the total lipids of the target glycemic monosodium derivative-modified ribosome.
- the resulting suspension was heated at 70 ° C. for 2 minutes to obtain a glycerol derivative-modified ribosome containing compound (2). This ribosome was prepared in 2 lots.
- glycemic monosaccharide derivative ribosome containing compound ( 2 ) (modification ratio: 15 mol%) 100 mmol / L citrate buffer (pH 4.0) was added to HSPC, and the mixture was shaken with a portex mixer. The resulting suspension was passed through a 0.4 ⁇ ra polycarbonate membrane filter four times at 70 ° C. and 10 times through a 0.1 ⁇ polycarbonate membrane filter. An unmodified liposome suspension was prepared so that the concentration of HSPC was 62.5 mg / mL by adding 100 ol / L of the taenoic acid buffer to the obtained solution.
- the unmodified ribosome suspension was added to doxorubicin so that the concentration of doxorubicin was 1.25 mg / raL.
- the pH value of the obtained suspension was adjusted to around 7.4 using lmol / L7ic aqueous sodium oxide solution, and then distilled water was added to adjust the doxorubicin concentration to lmg / mL.
- the obtained suspension was heated at 70 ° C for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin.
- Example 7 The suspension of the unmodified ribosome containing doxorubicin was added to an ethanol solution of the compound (2) obtained in Example 1 (amount of ethanol: 1 volume of the suspension of the unmodified liposome containing doxorubicin). %) was added so that the content of compound (2) was 15 mol% of the total lipids of the target glycerol derivative-modified ribosome. The resulting suspension was heated at 70 ° C for 2 minutes to obtain a glycerol derivative-modified ribosome containing compound (2).
- Example 7 Example 7
- the unmodified liposome suspension was added to doxorubicin so that the concentration of doxorubicin became 1.25 mg / mL.
- distilled water was added to adjust the doxorubicin concentration to Irag / mL.
- the obtained suspension was heated at 70 ° C for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin.
- a suspension of the unmodified ribosome containing doxorubicin was added to an ethanol solution of the compound (4) obtained in Example 2 (amount of ethanol: unmodified liposome containing doxorubicin).
- the unmodified liposome suspension was added to doxorubicin so that the concentration of doxorubicin became 1.25 mg / mL.
- the pH value of the obtained suspension was adjusted to around 7.4 using lraol / L aqueous sodium hydroxide solution, and then distilled water was added to adjust the doxorubicin concentration to lmg / mL.
- the obtained suspension was heated at 70 ° C for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin.
- the suspension of the unmodified ribosome containing doxorubicin was added to an ethanol solution of the compound (4) obtained in Example 2 (amount of ethanol: one volume of the suspension of the unmodified liposome containing doxorubicin). ./.) was added so that the content of compound (4) would be 15 mol% of the total lipid of the target glycerol derivative.
- the resulting suspension was heated at 70 ° C. for 2 minutes to obtain a glycerol derivative-modified ribosome containing compound ′ ( 4 ).
- the pH value of the obtained suspension was adjusted to about 7.4 using an lmol / L aqueous sodium fluoride solution, and then distilled water was added to adjust the doxorubicin concentration to 1 mg / mL.
- the obtained suspension was heated at 70 ° C for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin. This ribosome was prepared in 2 lots.
- the pH value of the obtained suspension was adjusted to about 7.4 using an lmol / L aqueous sodium hydroxide solution, and then distilled water was added to adjust the doxorubicin concentration to 1 mg / mL.
- the resulting suspension was heated at 70 ° C. for 5 minutes to prepare a suspension of unmodified ribosome containing doxorubicin.
- PEG-DSPE (1,2-distearoyl- sn -glycose-3-phosphoethanolamine-N- [poly (ethylene glycol) -2000] was added to the suspension of the unmodified ribosome containing doxorubicin.
- a compound or a salt thereof in which an amphipathic substance or a hydrophobic substance is modified with a glycerol derivative, and a fine particle containing the same, which are useful as, for example, a surface modifier for producing a drug carrier. Is done.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513728A JP4804923B2 (ja) | 2003-09-03 | 2004-09-03 | グリセロール誘導体で修飾された化合物 |
EP04772926A EP1666486A4 (en) | 2003-09-03 | 2004-09-03 | MODIFIED COMPOUND USING A GLYCEROL DERIVATIVE |
US10/570,623 US7696359B2 (en) | 2003-09-03 | 2004-09-03 | Compound modified with glycerol derivative |
CN2004800305856A CN1867580B (zh) | 2003-09-03 | 2004-09-03 | 被甘油衍生物修饰的化合物 |
US12/708,714 US20100172967A1 (en) | 2003-09-03 | 2010-02-19 | Compound modified with glycerol derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-311436 | 2003-09-03 | ||
JP2003311436 | 2003-09-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/708,714 Division US20100172967A1 (en) | 2003-09-03 | 2010-02-19 | Compound modified with glycerol derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023844A1 true WO2005023844A1 (ja) | 2005-03-17 |
Family
ID=34269696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013187 WO2005023844A1 (ja) | 2003-09-03 | 2004-09-03 | グリセロール誘導体で修飾された化合物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US7696359B2 (ja) |
EP (1) | EP1666486A4 (ja) |
JP (1) | JP4804923B2 (ja) |
KR (1) | KR20070019941A (ja) |
CN (1) | CN1867580B (ja) |
WO (1) | WO2005023844A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008093655A1 (ja) * | 2007-01-30 | 2008-08-07 | The University Of Tokushima | ポリアルコール化合物および医薬 |
EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
JP2011178698A (ja) * | 2010-02-26 | 2011-09-15 | Univ Of Tokushima | 5−ヒドロキシ−1,3−ジオキサンの製造方法および該方法により得られた5−ヒドロキシ−1,3−ジオキサンを原料とした分岐型グリセロール3量体の製造方法 |
JP2012522038A (ja) * | 2009-03-31 | 2012-09-20 | ユニベルシテ ダンジュ | 官能化された脂質カプセルを調製する為の方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7569706B2 (en) * | 2002-09-26 | 2009-08-04 | Kyowa Hakko Kirin Co., Ltd. | Glycerol derivative |
WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
SG171340A1 (en) * | 2008-11-19 | 2011-07-28 | Avantor Performance Mat Inc | New chromatographic media based on phenoxy alkyl and alkoxy-or phenoxy-phenyl alkyl ligands |
WO2013035899A1 (ko) * | 2011-09-07 | 2013-03-14 | 주식회사 코리아테크노에이전시 | 5-히드록시-1, 3-디옥산의 제조 방법 및 이를 원료로 한 분기형 글리세롤 3량체의 제조 방법 |
US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US10716802B2 (en) | 2013-03-15 | 2020-07-21 | The Brigham And Women's Hospital, Inc. | Compounds to modulate intestinal absorption of nutrients |
WO2017053970A1 (en) | 2015-09-24 | 2017-03-30 | The Brigham And Women's Hospital, Inc. | Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients |
GB201814356D0 (en) * | 2018-09-04 | 2018-10-17 | Univ Oxford Innovation Ltd | Methods of detergents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325271A (ja) * | 1995-05-31 | 1996-12-10 | Nippon Alkyl Alum Kk | p−ボロノフェニルアラニン誘導体、その製造方法及び該誘導体の中間体化合物 |
WO2004029018A1 (ja) * | 2002-09-26 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | グリセロール誘導体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
US6132763A (en) | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
JPH06228012A (ja) | 1993-01-29 | 1994-08-16 | Dai Ichi Seiyaku Co Ltd | リポソーム製剤 |
JP3570561B2 (ja) * | 1993-07-27 | 2004-09-29 | テルモ株式会社 | 血管内皮損傷部位を認識する担体 |
JP4827277B2 (ja) * | 1998-11-02 | 2011-11-30 | テルモ株式会社 | リポソーム |
AU770390B2 (en) * | 1999-04-23 | 2004-02-19 | Alza Corporation | Releasable linkage and compositions containing same |
JP2001064158A (ja) * | 1999-06-25 | 2001-03-13 | Terumo Corp | リポソーム |
-
2004
- 2004-09-03 KR KR1020067004439A patent/KR20070019941A/ko not_active Application Discontinuation
- 2004-09-03 EP EP04772926A patent/EP1666486A4/en not_active Withdrawn
- 2004-09-03 US US10/570,623 patent/US7696359B2/en not_active Expired - Fee Related
- 2004-09-03 WO PCT/JP2004/013187 patent/WO2005023844A1/ja active Application Filing
- 2004-09-03 JP JP2005513728A patent/JP4804923B2/ja not_active Expired - Fee Related
- 2004-09-03 CN CN2004800305856A patent/CN1867580B/zh not_active Expired - Fee Related
-
2010
- 2010-02-19 US US12/708,714 patent/US20100172967A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325271A (ja) * | 1995-05-31 | 1996-12-10 | Nippon Alkyl Alum Kk | p−ボロノフェニルアラニン誘導体、その製造方法及び該誘導体の中間体化合物 |
WO2004029018A1 (ja) * | 2002-09-26 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | グリセロール誘導体 |
Non-Patent Citations (5)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008093655A1 (ja) * | 2007-01-30 | 2008-08-07 | The University Of Tokushima | ポリアルコール化合物および医薬 |
EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
JP2011516415A (ja) * | 2008-03-10 | 2011-05-26 | ミフェニオン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 生物標的用のエフェクター分子を伴うポリエーテルポリオールデンドロン複合体 |
JP2012522038A (ja) * | 2009-03-31 | 2012-09-20 | ユニベルシテ ダンジュ | 官能化された脂質カプセルを調製する為の方法 |
US9333181B2 (en) | 2009-03-31 | 2016-05-10 | Universite D'angers | Method for preparing functionalized lipid capsules |
JP2011178698A (ja) * | 2010-02-26 | 2011-09-15 | Univ Of Tokushima | 5−ヒドロキシ−1,3−ジオキサンの製造方法および該方法により得られた5−ヒドロキシ−1,3−ジオキサンを原料とした分岐型グリセロール3量体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20070019941A (ko) | 2007-02-16 |
US20060280784A1 (en) | 2006-12-14 |
JPWO2005023844A1 (ja) | 2007-11-01 |
EP1666486A1 (en) | 2006-06-07 |
CN1867580B (zh) | 2010-09-29 |
US20100172967A1 (en) | 2010-07-08 |
CN1867580A (zh) | 2006-11-22 |
EP1666486A4 (en) | 2006-12-06 |
JP4804923B2 (ja) | 2011-11-02 |
US7696359B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110325511B (zh) | 用于rna递送的可离子化阳离子脂质 | |
TWI805577B (zh) | 靶向組合物 | |
JP6987641B2 (ja) | シリコン系薬物複合体及びその使用方法 | |
JP6182457B2 (ja) | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 | |
JP6182458B2 (ja) | カチオン性脂質の組み合わせを含有する脂質ナノ粒子 | |
WO2017117530A1 (en) | Ionizable cationic lipid | |
US20100172967A1 (en) | Compound modified with glycerol derivative | |
TW201726599A (zh) | 陽離子性脂質 | |
CN112262122A (zh) | 化合物或其盐及脂质颗粒 | |
WO2018225871A1 (ja) | カチオン性脂質としての化合物 | |
WO2022173531A9 (en) | Compounds, compositions, and methods of using thereof | |
WO2016002753A1 (ja) | カチオン性脂質 | |
TW201309621A (zh) | 新穎脂質 | |
WO2008089602A1 (fr) | Anthraquinones tétracycliques possédant un effet anticancéreux | |
WO2017111172A1 (ja) | カチオン性脂質としての化合物 | |
CN114874106B (zh) | 一种氨基脂质及其制备方法和应用 | |
WO2010026621A1 (ja) | ポリカチオン化リン脂質誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030585.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004772926 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513728 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006280784 Country of ref document: US Ref document number: 10570623 Country of ref document: US Ref document number: 1020067004439 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004772926 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10570623 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067004439 Country of ref document: KR |